Evidence map›Paper›PMID 33817217›Full record

ArticleOpen life sciences2020

Long non-coding RNA TUG1 knockdown hinders the tumorigenesis of multiple myeloma by regulating the microRNA-34a-5p/NOTCH1 signaling pathway.

Yongtian Zhang, Dandan Zhao, Shumei Li, Meng Xiao, Hongjing Zhou, Shuige Yang, Yunliang Hao, Shasha Dong

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Open life sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Yongtian ZhangDepartment of Hematology, Ji'ning No. 1 People's Hospital, Ji'ning, Shandong, China.
Dandan ZhaoDepartment of Hematology, Ji'ning No. 1 People's Hospital, Ji'ning, Shandong, China.
Shumei LiDepartment of Hematology, Ji'ning No. 1 People's Hospital, Ji'ning, Shandong, China.
Meng XiaoDepartment of Hematology, Ji'ning No. 1 People's Hospital, Ji'ning, Shandong, China.
Hongjing ZhouDepartment of Hematology, Ji'ning No. 1 People's Hospital, Ji'ning, Shandong, China.
Shuige YangDepartment of Hematology, Ji'ning No. 1 People's Hospital, Ji'ning, Shandong, China.
Yunliang HaoDepartment of Hematology, Ji'ning No. 1 People's Hospital, Ji'ning, Shandong, China.
Shasha DongDepartment of Hematology, Ji'ning No. 1 People's Hospital, Ji'ning, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is a serious health issue in hematological malignancies. Long non-coding RNA taurine-upregulated gene 1 (TUG1) has been reported to be highly expressed in the plasma of MM patients. However, the functions of TUG1 in MM tumorigenesis along with related molecular basis are still undefined. In this study, increased TUG1 and decreased microRNA-34a-5p (miR-34a-5p) levels in MM tissues and cells were measured by the real-time quantitative polymerase reaction assay. The expression of relative proteins was determined by the Western blot assay. TUG1 knockdown suppressed cell viability, induced cell cycle arrest and cell apoptosis in MM cells, as shown by Cell Counting Kit-8 and flow cytometry assays. Bioinformatics analysis, luciferase reporter assay, and RNA pull-down assay indicated that miR-34a-5p was a target of TUG1 and directly bound to notch receptor 1 (NOTCH1), and TUG1 regulated the NOTCH1 expression by targeting miR-34a-5p. The functions of miR-34a-5p were abrogated by TUG1 upregulation. Moreover, TUG1 loss impeded MM xenograft tumor growth

Indexed as

long non-coding RNAmicroRNA-34a-5pmultiple myelomaNOTCH1TUG1

Identifiers

PMID33817217
PMCPMC7874539
OpenAlexW3036494891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.